Chikungunya Vaccine Shows Promise in Adults
TOPLINE: The chikungunya virus virus-like particle (CHIKV VLP) vaccine achieved 100% seroconversion in adults who had previously received alphavirus vaccines and alphavirus vaccine–naive control individuals, with the previous recipients showing a faster immune response. Moreover, both groups had similar safety profiles. METHODOLOGY: Researchers conducted an open-label, phase 2, randomized controlled trial at two clinical sites … Read more